Field Guide · The Honest Read

Low-dose naltrexone.
For autism & PANS, honestly.

LDN is one of the gentler, more reversible options on the “what hasn’t been tried” menu — a tiny dose of an old drug, used to calm an over-activated immune system. The rationale is sound and the risk is low. But the evidence for autism and PANS is limited, and an older line of research was disappointing. Here’s the honest version, so you can weigh it with clear eyes.

A low-risk trial worth considering is not the same as a proven treatment — and we’ll keep those two ideas separate for you.

The one-line honest answer

LDN has a plausible anti-inflammatory rationale and is low-risk and reversible — which is why many PANS and autism clinicians trial it. But the controlled evidence is thin: there’s no large trial proving it changes autism or PANS, and older standard-dose naltrexone research for autism behavior was largely a disappointment. Best framed as a reasonable, low-stakes trial under a prescriber — not a proven therapy, and never a cure.

What LDN is & the theory behind it

Naltrexone is an old, generic opioid-blocking drug. At its standard dose (around 50 mg) it’s used for addiction. Low-dose naltrexone (LDN) uses a tiny fraction — roughly 0.5 to 4.5 mg, compounded by a specialty pharmacy and usually taken at bedtime.

The theory: a brief, low-dose blockade of opioid receptors triggers a rebound that raises the body’s own endorphins and calms immune and inflammatory signaling (including microglial activation in the brain). For an immune-driven PANS picture — or the inflammatory layer some autistic children carry — that’s a mechanistically coherent target. Coherent rationale is a reason to ask the question, not proof of the answer.

For the full deconstruction — mechanism, compounding, dosing, what to expect starting it — see the main LDN explainer.

What the evidence actually shows

Here’s the straight version. The honesty matters most here, because the strength of the rationale runs ahead of the strength of the data.

The supportive signals

  • A real anti-inflammatory track record in other conditions. LDN has small but genuine supportive evidence in conditions like fibromyalgia and Crohn’s — which is where the immune-calming rationale comes from. LDN as an anti-inflammatory agent, review (PMC)
  • Clinical experience in PANS and autism. Some clinicians report LDN helps with irritability, mood, and inflammation, and it’s appeared in PANS treatment discussions as an adjunct. This is real-world observation, not trial proof.
  • It’s low-risk and reversible — which is part of why a trial is reasonable even where the evidence is thin.

The sobering side — where the data is thin or disappointing

  • No large controlled trials of LDN specifically for autism or PANS. The support is rationale plus clinician experience plus extrapolation from other conditions — not gold-standard proof.
  • The older naltrexone-for-autism research was largely disappointing. In the 1990s, standard-dose naltrexone was studied for autism behavior; while some children showed reduced hyperactivity, it did not meaningfully improve the core social and communication features, and enthusiasm faded. LDN is a different dose and rationale, but that history is an honest caution against over-promising. Naltrexone in autism, controlled study (PubMed)
  • Reports of benefit are easy to over-read. Mood and irritability fluctuate, and without controls it’s hard to separate the drug from expectation and natural variation.

The honest label: plausible and low-risk, but unproven. LDN is a reasonable, reversible trial for the right child — especially where there’s a genuine inflammatory or immune layer — with modest expectations and a clear way to judge whether it’s helping. It is not a proven autism or PANS treatment, and it is not a cure.

Dosing & what to expect — the practical version

Read this as “what clinicians typically do,” not a prescription. LDN must be prescribed and compounded; your prescriber sets the dose for your child.

VariableTypical for a kidWhy
Starting doseVery low — often ~0.5–1.5 mg at bedtimeStart low to avoid the most common early side effects; raise slowly.
Target rangeCommonly ~1.5–4.5 mg, titrated by responseThe “low-dose” window where the immune-modulating effect is thought to live.
FormCompounded liquid or low-dose capsuleStandard pills are far too strong; a compounding pharmacy makes the small dose.
TimingOften bedtime (sometimes shifted earlier)Targets the overnight endorphin rebound; moving earlier can ease vivid dreams.

What to expect early

  • Vivid dreams or disrupted sleep — the most common early effect; usually settles, or eased by dosing earlier or lowering the dose.
  • Occasionally headache or mild GI upset in the first days.
  • Give it time — any immune-calming benefit tends to show over weeks, not days; change one thing at a time so you can read it.

The safety rules that actually matter

  • It blocks opioids. Naltrexone — even low-dose — cannot be combined with opioid pain medication, and your team needs to know before any procedure or surgery. This is the one hard rule.
  • It must be prescribed and managed by a clinician and compounded by a real pharmacy — not bought informally.
  • It’s reversible: the “off switch” is simply stopping it, with no lingering agent — one of the reassuring things about it.

Free Synthesis

Is there an inflammatory or immune layer LDN might actually help — or is the next step elsewhere? Plan B reads your child’s symptoms, history, and any labs together and tells you honestly whether LDN belongs on your table, and what to ask your prescriber. Your first Synthesis is free.

Start your free Synthesis → Parent education, not medical advice. No cure claims. You stay in charge.

Where to go from here

Bottom line

LDN is a low-risk, reversible option with a plausible immune-calming rationale — which is why it’s a reasonable trial for some PANS and autism kids, especially where there’s a real inflammatory layer. But the controlled evidence is limited, older naltrexone-for-autism research was largely disappointing, and it is not a proven treatment and not a cure. If you trial it: under a prescriber, started low, with modest expectations, a clear way to judge benefit, and the opioid-interaction rule respected. This is parent education, not medical advice — bring it to your team as questions.

How Plan B stays honest

Plan B does not partner with drug companies or doctors, and we never endorse anyone whose healing isn’t verified by families. We show you the options and how to vet them yourself — and we’re building parent verification: look up a clinic or practitioner and see real family reviews before you trust them. Universal bad reviews? Skip.

← Back to the Field Guide